Sionna Therapeutics, Inc.
sionnatx.comWhat Do They Do?
Develops small-molecule drug candidates for people with cystic fibrosis, including medicines designed to stabilize the CFTR protein and complementary CFTR modulators.
10-K for FY2025, filed Mar 2, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$29.9MView ↗
- ▲ +65% (Loss)
- vs −$18.1M in Q2 FY2025
-
Sep 9, 2026
Restructures to focus on SION-451 and SION-2222; ends SION-719 add-on program
Plans to advance the dual combination into a Phase 2a trial; the workforce reduction and SION-719 program wind-down are intended to extend cash runway.
Sources
8-K, filed Sep 14, 2026
On September 9, 2026, the Board of Directors (the “Board”) of Sionna Therapeutics, Inc. (the “Company”) approved a restructuring plan (the…View ↗
-
Aug 10, 2026
SION-719 trial misses its activity endpoint; company stops add-on development
SION-451 + SION-2222 was identified as the preferred dual combination.
Sources
8-K, filed Aug 10, 2026
Based on the totality of the data and target coverage observed, SION-451 + SION-2222 was identified as the preferred dual combination.View ↗
Who Do They Compete With?
Competes with Vertex and Fair Therapeutics
10-K for FY2025, filed Mar 2, 2026In particular, we expect to compete with Vertex, which has multiple approved products, as well as additional product candidates in…View ↗
Loading...
